References
- Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010;2010:479364. https://doi.org/10.1155/2010/479364
- Lee JH, Jo WH, Park PK, Kim JH, Jang WY, Kim HY, et al. A Survey of the Use of Antiepileptic Drugs in Stroke Patients. J Korean Neurol Assoc 2013;31(2):101-7.
- Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16(10):695-714. https://doi.org/10.2165/00023210-200216100-00004
- Aronson JK. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th edition. Amsterdam: Elsevier; 2016, p. 303-37.
- Morgan JC, Kurek JA, Davis JL, Sethi KD. Insights into Pathophysiology from Medication-induced Tremor. Tremor Other Hyperkinet Mov(NY) 2017;7:442. https://doi.org/10.5334/tohm.374
- Morgan JC, Sethi KD. Drug-induced tremors. Lancet Neurol 2005;4(12):866-76. https://doi.org/10.1016/S1474-4422(05)70250-7
- Zadikoff C, Munhoz RP, Asante AN, Politzer N, Wennberg R, Carlen P, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007;78(2):147-51. https://doi.org/10.1136/jnnp.2006.100222
- Zhang CQ, He BM, Hu ML, Sun HB. Risk of Valproic Acid-Related Tremor: A Systematic Review and Meta-Analysis. Front Neurol 2020;11:576579. https://doi.org/10.3389/fneur.2020.576579
- Silver M, Factor SA. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord 2013;19(8):758-60. https://doi.org/10.1016/j.parkreldis.2013.03.016
- Jankovic J, Tolosa E. Parkinson's disease and movement disorders. 2nd ed. Baltimore: Williams and Wilkins; 1993, p. 271-80.
- Elble R, Bain P, Forjaz MJ, Haubenberger D, Testa C, Goetz CG, et al. Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord 2013;28(13):1793-800. https://doi.org/10.1002/mds.25648
- Zelano J, Holtkamp M, Agarwal N, Lattanzi S, Trinka E, Brigo F. How to diagnose and treat post-stroke seizures and epilepsy. Epileptic Disord 2020 Jun 1;22(3):252-63. https://doi.org/10.1684/epd.2020.1159
- Culpepper L, Wingertzahn MA. Over-the-Counter Agents for the Treatment of Occasional Disturbed Sleep or Transient Insomnia: A Systematic Review of Efficacy and Safety. Prim Care Companion CNS Disord 2015;17(6):10.4088/PCC.15r01798.
- Monti JM, Monti D. Histamine H 1 receptor antagonists in the treatment of insomnia. CNS drugs 2000;13(2):87-96. https://doi.org/10.2165/00023210-200013020-00002
- Zlott DA, Byrne M. Mechanisms by which pharmacologic agents may contribute to fatigue. PM&R 2010;2(5):451-5. https://doi.org/10.1016/j.pmrj.2010.04.018
- Sweetman S. Martindale: The Complete Drug Reference. 36th edition. London: Pharmaceutical Press; 2009, p. 561, 577.
- Scharman EJ, Erdman AR, Wax PM, Chyka PA, Caravati EM, Nelson LS, et al. Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2006;44(3):205-23. https://doi.org/10.1080/15563650600585920
- Kuo CC, Huang RC, Lou BS. Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol Pharmacol 2000;57(1):135-43.
- Heo K. New antiepileptic drugs. J Korean Med Assoc 2012;55(2):155-73. https://doi.org/10.5124/jkma.2012.55.2.155
- World Health Organization (WHO). The use of the WHO- UMC system for the standardized case causality assessment. 2013. [online][cited on Nov. 19 2021]. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
- Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356(9237):1255-9. https://doi.org/10.1016/S0140-6736(00)02799-9
- Masmoudi K, Gras-Champel V, Masson H, Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006;39(1):9-12. https://doi.org/10.1055/s-2006-931471
- Farkas Z, Gulyas S, Molnar R, Szirmai I, Kamondi AJS. Quantitative analysis of motor performance in epilepsy patients treated with valproate. Seizure 2010;19(3):173-7. https://doi.org/10.1016/j.seizure.2010.01.013
- Spisak T, Roman V, Papp E, Kedves R, Saghy K, Csol e CK, et al. Purkinje cell number-correlated cerebrocerebellar circuit anomaly in the valproate model of autism. Sci Rep 2019;9(1):9225. https://doi.org/10.1038/s41598-019-45667-1
- Li Y, Zhou Y, Peng L, Zhao Y. Reduced protein expressions of cytomembrane GABAARβ3 at different postnatal developmental stages of rats exposed prenatally to valproic acid. Brain Res 2017;1671:33-42. https://doi.org/10.1016/j.brainres.2017.06.018
- Paparella G, Angelini L, De Biase A, Cannavacciuolo A, Colella D, Di Bonaventura C, et al. Clinical and Kinematic Features of Valproate-Induced Tremor and Differences with Essential Tremor. Cerebellum. 2021;20(3):374-83. https://doi.org/10.1007/s12311-020-01216-5
- Lee JM. Donguisusebowon (Constitutional Medicine in the East). Seoul: Yeokang Publishing; 1992, p. 74-164.
- Kim JH, Song JM. A Study about modification of Gejitang that showed on symptom and prescription about Soumin. J Sasang Constitut Med 1999;11(1):201-20.